Is hyperprogressive disease a specific phenomenom of immunotherapy?

Marta BrambillaGiuseppe Lo RussoRoberto Ferrara Sara ManglavitiMarina Chiara GarassinoMario Alberto Occhipinti

Published in: Exploration of targeted anti-tumor therapy (2020)

Hyperprogressive disease (HPD) is a novel pattern of response during immunotherapy treatment. Several retrospective studies have evaluated its prevalence among various cancer types and, in particular, in non-small cell lung cancer patients, based on different definition criteria. If HPD is a just a typical phenomenon of immunotherapy is still an unsolved concern. This paper summarized the available data about HPD in other cancer treatments.

Keyphrases

papillary thyroid
squamous cell
risk factors
stem cells
electronic health record
big data
mesenchymal stem cells
deep learning
smoking cessation